Claims for Patent: 8,952,018
✉ Email this page to a colleague
Summary for Patent: 8,952,018
| Title: | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
| Abstract: | A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}ac- etamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- -fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer. |
| Inventor(s): | Dumble; Melissa (Collegeville, PA), Kumar; Rakesh (Collegeville, PA), Laquerre; Sylvie (Collegeville, PA), Lebowitz; Peter (Collegeville, PA) |
| Assignee: | GlaxosmithKline LLC (Philadelphia`, PA) |
| Application Number: | 14/197,421 |
| Patent Claims: |
1. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I)
##STR00025## or a pharmaceutically acceptable salt or solvate thereof; and (ii) a compound of formula (II) ##STR00026## or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein compound (I) is in the form of the dimethyisulfoxide solvate. 3. The method of claim 1, wherein compound (II) is in the form of the methanesulfonate salt. 4. The method of claim 1, wherein the non-small cell lung cancer is BRAF V600E mutant non-small cell lung cancer. 5. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00027## or a pharmaceutically acceptable salt thereof; and (ii) a compound of formula (II) ##STR00028## or a pharmaceutically acceptable salt thereof. |
